

New Drug Modalities: Evolving Needs in Scientific Informatics



AGENDA

4:00 PM CEST | 10:00 AM EDT | 7:00 AM PDT

PLENARY SESSION

50 min

AUDITORIUM

New Modalities – A promise or a pain-point from a drug design perspective?



Leonardo De Maria, Ph.D.
Principal Scientist at AstraZeneca



4:50 PM CEST | 10:50 AM EDT | 7:50 AM PDT

BREAK - 10 MIN

5:00 PM CEST | 11:00 AM EDT | 8:00 AM PDT

TALK

30 min

AUDITORIUM

BioAIM: Building the next digital biologics platform for large molecule at Sanofi



Yves Fomekong Nanfack, Ph.D.
ED - Head of End to End AI Foundations. Large Molecules Research Platform at Sanofi



5:30 PM CEST | 11:30 AM EDT | 8:30 AM PDT

TALK

30 min

AUDITORIUM

Data science for new modalities: Challenges and opportunities



Barbara Brannetti, Ph.D.
Director Data Science, Characterization and Formulation at Novartis Institutes for BioMedical Research (NIBR)



6:00 PM CEST | 12:00 AM EDT | 9:00 AM PDT

BREAK - 15 MIN

6:15 PM CEST | 12:15 PM EDT | 9:15 AM PDT

ROUND TABLE

45 min

AUDITORIUM

What is the state of the art in new drug modalities discovery? - Present and future outlook

CHAIR



Thierry Dorval, Ph.D. Head of Sciences & Data management at Servier

PANELISTS



Philippe Archambault, Ph.D.
Application Scientist at Chemical Computing Group (CCG)



Kenneth Longo, Ph.D.
Vice President, Discovery Data Science at Wave Life Sciences



Barbara Brannetti, Ph.D.
Director Data Science, Characterization and Formulation at Novartis (NIBR)



Lars Brive, Ph.D.
Cheminformatics Data Scientists at AstraZeneca

7:00 PM CEST | 1:00 PM EDT | 10:00 AM PDT

AFTER PARTY - MEET THE SPEAKERS

VIRTUAL BAR

